A citation-based method for searching scientific literature

Jian Zhou, Francisco Sanchez-Vega, Raul Caso, Kay See Tan, Whitney S Brandt, Gregory D Jones, Shi Yan, Prasad S Adusumilli, Matthew Bott, James Huang, James M Isbell, Smita Sihag, Daniela Molena, Valerie W Rusch, Walid K Chatila, Natasha Rekhtman, Fan Yang, Marc Ladanyi, David B Solit, Michael F Berger, Nikolaus Schultz, David R Jones. Clin Cancer Res 2019
Times Cited: 9







List of co-cited articles
38 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Oncogenic Signaling Pathways in The Cancer Genome Atlas.
Francisco Sanchez-Vega, Marco Mina, Joshua Armenia, Walid K Chatila, Augustin Luna, Konnor C La, Sofia Dimitriadoy, David L Liu, Havish S Kantheti, Sadegh Saghafinia,[...]. Cell 2018
797
33

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.
Jianjun Zhang, Junya Fujimoto, Jianhua Zhang, David C Wedge, Xingzhi Song, Jiexin Zhang, Sahil Seth, Chi-Wan Chow, Yu Cao, Curtis Gumbs,[...]. Science 2014
587
33


Multiple primary lung cancers.
N Martini, M R Melamed. J Thorac Cardiovasc Surg 1975
739
33

Tracking the Evolution of Non-Small-Cell Lung Cancer.
Mariam Jamal-Hanjani, Gareth A Wilson, Nicholas McGranahan, Nicolai J Birkbak, Thomas B K Watkins, Selvaraju Veeriah, Seema Shafi, Diana H Johnson, Richard Mitter, Rachel Rosenthal,[...]. N Engl J Med 2017
957
33

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Donavan T Cheng, Talia N Mitchell, Ahmet Zehir, Ronak H Shah, Ryma Benayed, Aijazuddin Syed, Raghu Chandramohan, Zhen Yu Liu, Helen H Won, Sasinya N Scott,[...]. J Mol Diagn 2015
906
33

APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
Charles Swanton, Nicholas McGranahan, Gabriel J Starrett, Reuben S Harris. Cancer Discov 2015
234
33

The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
Raul Caso, Francisco Sanchez-Vega, Kay See Tan, Brooke Mastrogiacomo, Jian Zhou, Gregory D Jones, Bastien Nguyen, Nikolaus Schultz, James G Connolly, Whitney S Brandt,[...]. J Thorac Oncol 2020
13
33

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Collin M Blakely, Thomas B K Watkins, Wei Wu, Beatrice Gini, Jacob J Chabon, Caroline E McCoach, Nicholas McGranahan, Gareth A Wilson, Nicolai J Birkbak, Victor R Olivas,[...]. Nat Genet 2017
245
22

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
Dara L Aisner, Lynette M Sholl, Lynne D Berry, Michael R Rossi, Heidi Chen, Junya Fujimoto, Andre L Moreira, Suresh S Ramalingam, Liza C Villaruz, Gregory A Otterson,[...]. Clin Cancer Res 2018
91
22

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.
Helena A Yu, Ken Suzawa, Emmet Jordan, Ahmet Zehir, Ai Ni, Ryan Kim, Mark G Kris, Matthew D Hellmann, Bob T Li, Romel Somwar,[...]. Clin Cancer Res 2018
109
22

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
507
22

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
955
22

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen,[...]. N Engl J Med 2017
22

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
Xiaoli Ma, Gwénaël Le Teuff, Benjamin Lacas, Ming Sound Tsao, Stephen Graziano, Jean-Pierre Pignon, Jean-Yves Douillard, Thierry Le Chevalier, Lesley Seymour, Martin Filipits,[...]. J Thorac Oncol 2016
50
22

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
22

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
Paul A VanderLaan, Deepa Rangachari, Susan M Mockus, Vanessa Spotlow, Honey V Reddi, Joan Malcolm, Mark S Huberman, Loren J Joseph, Susumu S Kobayashi, Daniel B Costa. Lung Cancer 2017
99
22


Genome doubling shapes the evolution and prognosis of advanced cancers.
Craig M Bielski, Ahmet Zehir, Alexander V Penson, Mark T A Donoghue, Walid Chatila, Joshua Armenia, Matthew T Chang, Alison M Schram, Philip Jonsson, Chaitanya Bandlamudi,[...]. Nat Genet 2018
130
22

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L Sauter, Natasha Rekhtman,[...]. J Clin Oncol 2018
610
22

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
22

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
22


The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
William D Travis, Elisabeth Brambilla, Andrew G Nicholson, Yasushi Yatabe, John H M Austin, Mary Beth Beasley, Lucian R Chirieac, Sanja Dacic, Edwina Duhig, Douglas B Flieder,[...]. J Thorac Oncol 2015
22

OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty, Jianjiong Gao, Sarah M Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E Rudolph, Rona Yaeger, Tara Soumerai, Moriah H Nissan,[...]. JCO Precis Oncol 2017
680
22

The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Hao Chen, Wei Chong, Changcai Teng, Yueliang Yao, Xin Wang, Xue Li. Cancer Sci 2019
44
22

The repertoire of mutational signatures in human cancer.
Ludmil B Alexandrov, Jaegil Kim, Nicholas J Haradhvala, Mi Ni Huang, Alvin Wei Tian Ng, Yang Wu, Arnoud Boot, Kyle R Covington, Dmitry A Gordenin, Erik N Bergstrom,[...]. Nature 2020
529
22

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
William D Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew G Nicholson, Kim R Geisinger, Yasushi Yatabe, David G Beer, Charles A Powell, Gregory J Riely, Paul E Van Schil,[...]. J Thorac Oncol 2011
22

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.
Craig H Mermel, Steven E Schumacher, Barbara Hill, Matthew L Meyerson, Rameen Beroukhim, Gad Getz. Genome Biol 2011
22

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
22

New approaches to molecular diagnosis.
Bruce R Korf, Heidi L Rehm. JAMA 2013
79
22

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.
Hideki Ujiie, Kyuichi Kadota, Jamie E Chaft, Daniel Buitrago, Camelia S Sima, Ming-Ching Lee, James Huang, William D Travis, Nabil P Rizk, Charles M Rudin,[...]. J Clin Oncol 2015
115
22

The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.
Arne Warth, Thomas Muley, Michael Meister, Albrecht Stenzinger, Michael Thomas, Peter Schirmacher, Philipp A Schnabel, Jan Budczies, Hans Hoffmann, Wilko Weichert. J Clin Oncol 2012
446
22

Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach.
Jason C Chang, Deepu Alex, Matthew Bott, Kay See Tan, Venkatraman Seshan, Andrew Golden, Jennifer L Sauter, Darren J Buonocore, Chad M Vanderbilt, Sounak Gupta,[...]. Clin Cancer Res 2019
24
22

A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.
Gregory D Jones, Whitney S Brandt, Ronglai Shen, Francisco Sanchez-Vega, Kay See Tan, Axel Martin, Jian Zhou, Michael Berger, David B Solit, Nikolaus Schultz,[...]. JAMA Surg 2021
7
28

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohe, Margarita Majem, Jonathan W Goldman, Konstantin Laktionov, Sang-We Kim, Terufumi Kato,[...]. N Engl J Med 2020
155
22

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw, Kari Chansky, John Crowley, Ramon Rami-Porta, Hisao Asamura, Wilfried E E Eberhardt, Andrew G Nicholson, Patti Groome, Alan Mitchell, Vanessa Bolejack. J Thorac Oncol 2016
22

Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer.
William C S Cho, Kien Thiam Tan, Victor W S Ma, Jacky Y C Li, Roger K C Ngan, Wah Cheuk, Timothy T C Yip, Yi-Ting Yang, Shu-Jen Chen. Oncotarget 2018
5
40

The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Helena J Janse van Rensburg, Taha Azad, Min Ling, Yawei Hao, Brooke Snetsinger, Prem Khanal, Lori M Minassian, Charles H Graham, Michael J Rauh, Xiaolong Yang. Cancer Res 2018
106
11

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Luping Lin, Amit J Sabnis, Elton Chan, Victor Olivas, Lindsay Cade, Evangelos Pazarentzos, Saurabh Asthana, Dana Neel, Jenny Jiacheng Yan, Xinyuan Lu,[...]. Nat Genet 2015
292
11

Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT.
Srinivas Malladi, Danilo G Macalinao, Xin Jin, Lan He, Harihar Basnet, Yilong Zou, Elisa de Stanchina, Joan Massagué. Cell 2016
322
11

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Sai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, Michael E Goldberg, Viola W Zhu, Lee Albacker, Philip J Stephens, Vincent A Miller, Siraj M Ali. Lung Cancer 2017
68
11

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
Paul K Paik, Maria E Arcila, Michael Fara, Camelia S Sima, Vincent A Miller, Mark G Kris, Marc Ladanyi, Gregory J Riely. J Clin Oncol 2011
431
11

Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
Nicolas Guibert, Anne Pradines, Magali Farella, Anne Casanova, Sandrine Gouin, Laura Keller, Gilles Favre, Julien Mazieres. Lung Cancer 2016
35
11

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs).
Jia Zhong, Lei Li, Zhijie Wang, Hua Bai, Fei Gai, Jianchun Duan, Jun Zhao, Minglei Zhuo, Yuyan Wang, Shuhang Wang,[...]. J Thorac Oncol 2017
26
11

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.
Fiamma Buttitta, Fabio Barassi, Giuseppina Fresu, Lara Felicioni, Antonio Chella, Diego Paolizzi, Giuseppe Lattanzio, Simona Salvatore, Pier P Camplese, Sandra Rosini,[...]. Int J Cancer 2006
124
11

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Maria E Arcila, Jamie E Chaft, Khedoudja Nafa, Sinchita Roy-Chowdhuri, Christopher Lau, Michael Zaidinski, Paul K Paik, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Clin Cancer Res 2012
258
11

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.
Xiuning Le, Sonam Puri, Marcelo V Negrao, Monique B Nilsson, Jacqulyne Robichaux, Theresa Boyle, J Kevin Hicks, Katherine L Lovinger, Emily Roarty, Waree Rinsurongkawong,[...]. Clin Cancer Res 2018
142
11

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients.
Xu-Chao Zhang, Jun Wang, Guo-Guang Shao, Qun Wang, Xiaotao Qu, Bo Wang, Christopher Moy, Yue Fan, Zayed Albertyn, Xiayu Huang,[...]. Nat Commun 2019
72
11

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.
Matteo Canale, Elisabetta Petracci, Angelo Delmonte, Elisa Chiadini, Claudio Dazzi, Maximilian Papi, Laura Capelli, Claudia Casanova, Nicoletta De Luigi, Marita Mariotti,[...]. Clin Cancer Res 2017
120
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.